- Home
- QH vs PROK Comparison
QH vs PROK Comparison
Compare QH & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QH
- PROK
- Stock Information
- Founded
- QH 2012
- PROK 2015
- Country
- QH China
- PROK United States
- Employees
- QH N/A
- PROK N/A
- Industry
- QH Business Services
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QH Consumer Discretionary
- PROK Health Care
- Exchange
- QH Nasdaq
- PROK Nasdaq
- Market Cap
- QH 104.9M
- PROK 85.5M
- IPO Year
- QH 2020
- PROK N/A
- Fundamental
- Price
- QH $1.30
- PROK $4.74
- Analyst Decision
- QH
- PROK Buy
- Analyst Count
- QH 0
- PROK 4
- Target Price
- QH N/A
- PROK $5.33
- AVG Volume (30 Days)
- QH 22.2K
- PROK 33.2M
- Earning Date
- QH 08-27-2025
- PROK 08-08-2025
- Dividend Yield
- QH N/A
- PROK N/A
- EPS Growth
- QH N/A
- PROK N/A
- EPS
- QH 0.01
- PROK N/A
- Revenue
- QH $417,431,053.00
- PROK $306,000.00
- Revenue This Year
- QH N/A
- PROK $54.34
- Revenue Next Year
- QH N/A
- PROK N/A
- P/E Ratio
- QH $144.82
- PROK N/A
- Revenue Growth
- QH N/A
- PROK N/A
- 52 Week Low
- QH $0.25
- PROK $0.46
- 52 Week High
- QH $2.27
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- QH 54.65
- PROK 92.14
- Support Level
- QH $1.16
- PROK $0.54
- Resistance Level
- QH $1.45
- PROK $7.13
- Average True Range (ATR)
- QH 0.09
- PROK 0.62
- MACD
- QH 0.01
- PROK 0.47
- Stochastic Oscillator
- QH 42.23
- PROK 68.59
About QH Quhuo Limited American Depository Shares
Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.